DK2391731T3 - Produktion af lukket, lineært dna - Google Patents

Produktion af lukket, lineært dna

Info

Publication number
DK2391731T3
DK2391731T3 DK10702726.0T DK10702726T DK2391731T3 DK 2391731 T3 DK2391731 T3 DK 2391731T3 DK 10702726 T DK10702726 T DK 10702726T DK 2391731 T3 DK2391731 T3 DK 2391731T3
Authority
DK
Denmark
Prior art keywords
closed
production
linear dna
dna
linear
Prior art date
Application number
DK10702726.0T
Other languages
Danish (da)
English (en)
Inventor
Vanessa Hill
Original Assignee
Touchlight Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2391731(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Touchlight Genetics Ltd filed Critical Touchlight Genetics Ltd
Application granted granted Critical
Publication of DK2391731T3 publication Critical patent/DK2391731T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6846Common amplification features
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y113/00Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK10702726.0T 2009-01-30 2010-02-01 Produktion af lukket, lineært dna DK2391731T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0901593.4A GB0901593D0 (en) 2009-01-30 2009-01-30 Production of closed linear DNA
PCT/GB2010/000165 WO2010086626A1 (en) 2009-01-30 2010-02-01 Production of closed linear dna

Publications (1)

Publication Number Publication Date
DK2391731T3 true DK2391731T3 (da) 2013-04-22

Family

ID=40469378

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10702726.0T DK2391731T3 (da) 2009-01-30 2010-02-01 Produktion af lukket, lineært dna
DK16195596.8T DK3150722T3 (da) 2009-01-30 2010-02-01 Produktion af lukket lineært dna

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16195596.8T DK3150722T3 (da) 2009-01-30 2010-02-01 Produktion af lukket lineært dna

Country Status (19)

Country Link
US (4) US9109250B2 (OSRAM)
EP (3) EP2391731B1 (OSRAM)
JP (2) JP2012516147A (OSRAM)
KR (1) KR101926662B1 (OSRAM)
CN (2) CN102301010B (OSRAM)
AU (1) AU2010209532B2 (OSRAM)
BR (1) BRPI1005683B1 (OSRAM)
CA (1) CA2751130C (OSRAM)
DK (2) DK2391731T3 (OSRAM)
EA (1) EA021069B1 (OSRAM)
ES (2) ES2749629T3 (OSRAM)
GB (1) GB0901593D0 (OSRAM)
IL (1) IL213930A (OSRAM)
LT (1) LT3150722T (OSRAM)
MX (1) MX2011007937A (OSRAM)
NZ (1) NZ594004A (OSRAM)
SG (1) SG173102A1 (OSRAM)
WO (1) WO2010086626A1 (OSRAM)
ZA (1) ZA201105013B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025190971A1 (fr) 2024-03-13 2025-09-18 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351294B8 (es) * 2009-07-02 2012-06-06 Consejo Superior De Investigaciones Científicas (Csic) Metodo para la replicación, amplificación, o secuenciación de un adn molde.
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9290800B2 (en) 2013-03-15 2016-03-22 Pacific Biosciences Of California, Inc. Targeted rolling circle amplification
GB201502645D0 (en) * 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
RU2616279C1 (ru) * 2015-12-28 2017-04-13 Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
DK3500682T3 (da) 2016-08-16 2020-08-24 Touchlight Ip Ltd Fremstilling af lukket, lineært dna
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109971825B (zh) * 2017-12-28 2020-11-10 南京金斯瑞生物科技有限公司 快速制备桑格测序模板的方法
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
CN112639110A (zh) * 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 用于基因递送以在细胞内持续存在的载体
CN113195001B (zh) * 2018-11-02 2025-04-29 耐克基因有限责任公司 重组细小病毒载体及其制备方法和用途
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
EP3986454A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
US20250041386A1 (en) 2019-06-18 2025-02-06 Janssen Sciences Ireland Unlimited Company Recombinant Interleukin 12 Construct and Uses Thereof
US20220305107A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
AU2020295796A1 (en) 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and HBV-targeting rnai
KR20220041079A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
EP3986457A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
EP3986563A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
EP3792367A1 (en) 2019-09-11 2021-03-17 Universität Bielefeld Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest
GB2606844B (en) 2019-09-18 2025-08-06 Aldevron Llc Synthetic DNA vectors and methods of use
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
AU2020407850A1 (en) 2019-12-20 2022-06-30 Keygene N.V. NGS library preparation using covalently closed nucleic acid molecule ends
US20230048994A1 (en) * 2020-01-17 2023-02-16 Asklepios Biopharmaceutical, Inc. Recombinant aav production
CN115023503A (zh) * 2020-01-31 2022-09-06 泰瑞斯疗法公司 生产闭合线性dna的方法
IL296024A (en) 2020-03-04 2022-10-01 Flagship Pioneering Innovations Vi Llc Methods and compositions for modulating a genome
GB202007428D0 (en) 2020-05-19 2020-07-01 Fabricnano Ltd Polynucleotide synthesis
US20230272378A1 (en) 2020-06-12 2023-08-31 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
KR20230058081A (ko) 2020-08-26 2023-05-02 스캔셀 리미티드 인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
WO2022074058A1 (en) 2020-10-06 2022-04-14 Keygene N.V. Targeted sequence addition
EP4317424A4 (en) 2021-03-29 2025-10-22 Kaneka Corp VECTOR, METHOD FOR PREPARING COVALENTLY BONDED CLOSED LINEAR DNA USING SAME, METHOD FOR PREPARING PARVOVIRAL VECTOR, AND PARVOVIRAL VECTOR PRODUCTION CELL
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
CA3222751A1 (en) 2021-06-08 2022-12-15 Touchlight IP Limited Lentiviral vector
US20230055381A1 (en) 2021-06-25 2023-02-23 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
WO2023285976A1 (en) 2021-07-13 2023-01-19 Stonehaven Incubate AG Composition and uses thereof
EP4124660A1 (en) 2021-07-30 2023-02-01 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
GB202114105D0 (en) 2021-10-01 2021-11-17 Fabricnano Ltd Nucleotide synthesis
US20250027107A1 (en) 2021-10-18 2025-01-23 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
US20230279433A1 (en) 2021-12-15 2023-09-07 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
CN118489008A (zh) * 2021-12-23 2024-08-13 世代生物公司 封闭端dna载体的可扩展且高纯度无细胞合成
CN114561372B (zh) * 2022-04-27 2022-07-26 南京巨匠生物科技有限公司 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
EP4570912A1 (en) 2022-08-10 2025-06-18 Zhenjiang Probio Biotech Co., Ltd. Method for preparing linear closed dna and plasmid for use in the method
WO2024058155A1 (ja) 2022-09-12 2024-03-21 株式会社カネカ 二本鎖環状dnaベクター、直鎖状共有結合閉鎖dnaの作製方法、並びにプロテロメラーゼ及びエンドヌクレアーゼを含む融合ポリペプチド
WO2024069549A1 (en) 2022-09-29 2024-04-04 Touchlight Aquaculture Limited Vaccine construct and uses thereof
EP4365303A1 (en) 2022-11-02 2024-05-08 4basebio, S.L.U. Purification of linear dna products
EP4612320A1 (en) 2022-11-02 2025-09-10 4basebio UK Ltd Purification of linear dna products
KR102753513B1 (ko) * 2022-11-18 2025-01-13 최낙식 Direct RNA 추출 버퍼 및 이의 용도
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
WO2024132094A1 (en) 2022-12-19 2024-06-27 Thermo Fisher Scientific Geneart Gmbh Retrieval of sequence-verified nucleic acid molecules
EP4410995A1 (en) 2023-02-01 2024-08-07 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
EP4410992B1 (en) 2023-02-01 2025-12-17 4basebio UK Ltd Linear dna with enhanced resistance against exonucleases and methods for the production thereof
WO2024197081A1 (en) 2023-03-20 2024-09-26 Hc Bioscience, Inc. Minimally-sized dna threads for trna therapy
CN116606834A (zh) * 2023-04-10 2023-08-18 天津中合基因科技有限公司 多种具有切割连接活性的原端酶及其应用
AU2024258816A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Generation of adeno-associated virus capsid libraries for insect cells
WO2024256842A1 (en) 2023-06-16 2024-12-19 Touchlight IP Limited Therapeutic transfection
US11981936B1 (en) 2023-09-29 2024-05-14 New England Biolabs, Inc. TelA variants, compositions, and methods
EP4553156A1 (en) 2023-11-08 2025-05-14 4basebio UK Ltd Synthetic dna production using cas nuclease
GB202319998D0 (en) 2023-12-22 2024-02-07 Touchlight Ip Ltd duplexing method
EP4596713A1 (en) 2024-02-05 2025-08-06 4basebio UK Ltd Dna with enhanced resistance against exonucleases and methods for the production thereof
WO2025194042A1 (en) 2024-03-14 2025-09-18 Affinia Therapeutics Inc. Plasmid system for production of recombinant adenoassociated virus
WO2025202929A1 (en) * 2024-03-29 2025-10-02 Pfizer Inc. Methods for producing nucleic acids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン,インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6953676B1 (en) 1992-05-01 2005-10-11 Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification device and method
WO1994003624A1 (en) 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
EP0636413B1 (en) 1993-07-28 2001-11-14 PE Corporation (NY) Nucleic acid amplification reaction apparatus and method
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JPH10234399A (ja) 1997-02-28 1998-09-08 Shinkinrui Kinou Kaihatsu Kenkyusho:Kk ピシウム属菌検出用の核酸配列
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6054274A (en) * 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
DE69839709D1 (de) 1997-12-24 2008-08-21 Cepheid Vorrichtung und Verfahren zur Lyse
US6620597B1 (en) 1998-01-09 2003-09-16 University Of Utah Research Foundation Method for in vitro amplification of circular DNA
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
CA2342838A1 (en) 1998-09-15 2000-03-23 Yale University Molecular cloning using rolling circle amplification
EP1203078B1 (de) * 1999-07-08 2005-05-04 Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
GB0018120D0 (en) 2000-07-24 2000-09-13 Fermentas Ab Nuclease
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030077611A1 (en) 2001-10-24 2003-04-24 Sention Methods and systems for dynamic gene expression profiling
CA2412187A1 (en) 2001-12-21 2003-06-21 University Of Western Ontario Assay for identifying modulators of borrelia telomere resolvase
US7081339B2 (en) 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
WO2004007684A2 (en) 2002-07-12 2004-01-22 Affymetrix, Inc. Synthetic tag genes
US20040022764A1 (en) 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
AU2003281917A1 (en) * 2002-09-23 2004-04-19 Mologen Ag Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
WO2004065582A2 (en) 2003-01-15 2004-08-05 Dana-Farber Cancer Institute, Inc. Amplification of dna in a hairpin structure, and applications
DE602004021235D1 (de) 2003-02-21 2009-07-09 Geneform Technologies Ltd Verfahren, kits und reagenzien zur nukleinsäuresequenzierung
EP1706502A4 (en) 2003-11-26 2007-05-23 Eppendorf Ag METHODS AND COMPOSITIONS FOR IN VITRO AMPLIFICATION OF EXTRACHROMOSOMIC NUCLEIC ACID
AU2005314431B2 (en) 2004-12-11 2011-02-17 Cytogenix, Inc. Cell free biosynthesis of high-quality nucleic acid and uses thereof
EP1871897B1 (en) 2005-04-12 2010-09-29 Olink AB Methods for production of oligonucleotides
AU2006242387B2 (en) 2005-04-29 2011-01-06 Synthetic Genomics, Inc. Amplification and cloning of single DNA molecules using rolling circle amplification
ATE537251T1 (de) 2005-10-06 2011-12-15 Lucigen Corp Temperaturstabile virale polymerasen und verwendungsverfahren
EP1974037B1 (en) 2006-01-12 2012-03-14 Lucigen Corporation Linear vectors, host cells and cloning methods
CN101589157B (zh) 2006-10-06 2014-04-02 万达利亚研究公司 用于连续快速热循环系统的方法
WO2008151023A2 (en) * 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9114399B2 (en) 2010-08-31 2015-08-25 Canon U.S. Life Sciences, Inc. System and method for serial processing of multiple nucleic acid assays
EP2692870A1 (en) 2012-08-03 2014-02-05 Alacris Theranostics GmbH Method for nucleic acid amplification
KR102014989B1 (ko) 2013-04-15 2019-08-27 삼성전자주식회사 폴리뉴클레오티드 및 그의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025190971A1 (fr) 2024-03-13 2025-09-18 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Also Published As

Publication number Publication date
CA2751130A1 (en) 2010-08-05
EP3150722A1 (en) 2017-04-05
BRPI1005683A2 (pt) 2019-04-02
ZA201105013B (en) 2013-03-27
MX2011007937A (es) 2011-08-17
US20190203282A1 (en) 2019-07-04
DK3150722T3 (da) 2019-12-16
JP2016047049A (ja) 2016-04-07
KR20110107846A (ko) 2011-10-04
US20150329902A1 (en) 2015-11-19
KR101926662B1 (ko) 2018-12-07
JP2012516147A (ja) 2012-07-19
BRPI1005683B1 (pt) 2019-11-12
ES2749629T3 (es) 2020-03-23
AU2010209532B2 (en) 2015-06-25
EP2612925A1 (en) 2013-07-10
WO2010086626A1 (en) 2010-08-05
EP3150722B1 (en) 2019-09-11
NZ594004A (en) 2013-01-25
EP2612925B1 (en) 2016-11-30
US11384388B2 (en) 2022-07-12
EA201101141A1 (ru) 2012-05-30
US20220372565A1 (en) 2022-11-24
EP2391731A1 (en) 2011-12-07
EA021069B1 (ru) 2015-03-31
JP6454243B2 (ja) 2019-01-16
CN102301010B (zh) 2015-07-08
EP2391731B1 (en) 2013-01-23
CN102301010A (zh) 2011-12-28
HK1159693A1 (en) 2012-08-03
CA2751130C (en) 2018-03-06
CN104911177A (zh) 2015-09-16
IL213930A0 (en) 2011-07-31
US9109250B2 (en) 2015-08-18
AU2010209532A1 (en) 2011-07-28
GB0901593D0 (en) 2009-03-11
SG173102A1 (en) 2011-08-29
US20120282283A1 (en) 2012-11-08
IL213930A (en) 2014-08-31
ES2400890T3 (es) 2013-04-15
LT3150722T (lt) 2019-12-10

Similar Documents

Publication Publication Date Title
DK2391731T3 (da) Produktion af lukket, lineært dna
IL252193A0 (en) Greenhouse
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DK2274417T3 (da) Cellulær produktion af glucarsyre
IT1400767B1 (it) Microsistema
HUE055338T2 (hu) Indolamin-2,3-dioxigenáz-alapú immunterápia
BR112012005146A2 (pt) fotobiorreator
EP2396152A4 (en) Router
BR112012000657A2 (pt) novos azabicilohexanos
PL2339910T3 (pl) Szklarnia
EP2516615A4 (en) IMPROVED BIOREACTORS
DK2451354T3 (da) Lancet
EP2399785A4 (en) slide assembly
BRPI1009018A2 (pt) fotobiorreator
FR2950073B1 (fr) Micro-plaque
DK2403820T3 (da) Kemisk fremgangsmåde til produktion af haloalkenonethere
BR112012010525A2 (pt) novos processos
FI20095664A0 (fi) Solukalvoprofiili
ES1071337Y (es) Punching-ball corredizo
FI9141U1 (fi) Apuväline
FIU20090267U0 (fi) Kasvihuone
ES1070867Y (es) Adorno magnetico versatil, oscilante publicitario
TH93130B (th) หน้าตัดโลหะ
TH93132B (th) หน้าตัดโลหะ
TH93127B (th) หน้าตัดโลหะ